He also worked on The Journal’s publishing desk; as a writer and editor covering stocks at Barron’s; as an editor of features at MarketWatch; and on product development efforts at The Journal.  ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Why Moderna Inc. (MRNA) is Skyrocketing? A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine. The latest guidance reduction was the second time in the ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...

Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...

Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also the company’s first commercial product—has notably struggled to ...

Moderna secures a multi-year agreement to supply its COVID-19 vaccine to 17 European countries, including Norway and North Macedonia. Vaccine formats include prefilled syringes, reducing ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the ...

MDV: Multidose vial; NA: Not available ... influenza vaccination campaign estimated that the total time to get a vaccine ready to be administered per patient was 87 s for MDVs and 49.71 s for ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.